Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Kisses Pharma Business Goodbye In $3.1 Billion Deal With Warner Chilcott

This article was originally published in The Pink Sheet Daily

Executive Summary

Ireland-based Warner Chilcott has a "double tax haven," making the P&G deal one with fairly low financial risks, Wall Street analysts say.

You may also be interested in...



P&G Pharma Sale Could Bring $1 Billion To Feed Consumer Business

A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says

Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel